ACST Stock Overview
Acasti Pharma Inc., a biopharmaceutical company, engages in the development and commercialization of pharmaceutical products for cardiovascular diseases.
+ 1 more risk
Acasti Pharma Competitors
Price History & Performance
|Historical stock prices|
|Current Share Price||CA$1.52|
|52 Week High||CA$12.40|
|52 Week Low||CA$1.33|
|1 Month Change||-19.15%|
|3 Month Change||-26.21%|
|1 Year Change||-79.35%|
|3 Year Change||-86.13%|
|5 Year Change||-88.55%|
|Change since IPO||-97.03%|
Recent News & Updates
|ACST||CA Pharmaceuticals||CA Market|
Return vs Industry: ACST underperformed the Canadian Pharmaceuticals industry which returned -57.8% over the past year.
Return vs Market: ACST underperformed the Canadian Market which returned 15% over the past year.
|ACST Average Weekly Movement||14.3%|
|Pharmaceuticals Industry Average Movement||11.6%|
|Market Average Movement||9.8%|
|10% most volatile stocks in CA Market||17.3%|
|10% least volatile stocks in CA Market||3.7%|
Stable Share Price: ACST is more volatile than 75% of Canadian stocks over the past 3 months, typically moving +/- 14% a week.
Volatility Over Time: ACST's weekly volatility (14%) has been stable over the past year, but is still higher than 75% of Canadian stocks.
About the Company
Acasti Pharma Inc., a biopharmaceutical company, engages in the development and commercialization of pharmaceutical products for cardiovascular diseases. It is evaluating strategic partnerships for the clinical development of CaPre, an omega-3 phospholipid therapeutic to treat patients with hypertriglyceridemia. The company was incorporated in 2002 and is headquartered in Laval, Canada.
Acasti Pharma Fundamentals Summary
|ACST fundamental statistics|
Is ACST overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|ACST income statement (TTM)|
|Cost of Revenue||US$76.00k|
Last Reported Earnings
Sep 30, 2021
Next Earnings Date
|Earnings per share (EPS)||-0.25|
|Net Profit Margin||-5,613.78%|
How did ACST perform over the long term?See historical performance and comparison
Is Acasti Pharma undervalued compared to its fair value and its price relative to the market?
Undervalued compared to fair value
Share Price vs. Fair Value
Below Fair Value: ACST (CA$1.52) is trading below our estimate of fair value (CA$48.53)
Significantly Below Fair Value: ACST is trading below fair value by more than 20%.
Price To Earnings Ratio
PE vs Industry: ACST is unprofitable, so we can't compare its PE Ratio to the Canadian Pharmaceuticals industry average.
PE vs Market: ACST is unprofitable, so we can't compare its PE Ratio to the Canadian market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate ACST's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: ACST is good value based on its PB Ratio (0.5x) compared to the CA Pharmaceuticals industry average (1.6x).
How is Acasti Pharma forecast to perform in the next 1 to 3 years based on estimates from 2 analysts?
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: ACST is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: ACST is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: ACST is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: ACST is forecast to have no revenue next year.
High Growth Revenue: ACST is forecast to have no revenue next year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if ACST's Return on Equity is forecast to be high in 3 years time
How has Acasti Pharma performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: ACST is currently unprofitable.
Growing Profit Margin: ACST is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: ACST is unprofitable, and losses have increased over the past 5 years at a rate of 3.6% per year.
Accelerating Growth: Unable to compare ACST's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: ACST is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (30.8%).
Return on Equity
High ROE: ACST has a negative Return on Equity (-9.63%), as it is currently unprofitable.
How is Acasti Pharma's financial position?
Financial Position Analysis
Short Term Liabilities: ACST's short term assets ($54.5M) exceed its short term liabilities ($4.5M).
Long Term Liabilities: ACST's short term assets ($54.5M) exceed its long term liabilities ($1.1M).
Debt to Equity History and Analysis
Debt Level: ACST is debt free.
Reducing Debt: ACST had no debt 5 years ago.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: ACST has sufficient cash runway for more than 3 years based on its current free cash flow.
Forecast Cash Runway: Insufficient data to determine if ACST has enough cash runway if its free cash flow continues to grow or shrink based on historical rates.
What is Acasti Pharma current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate ACST's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate ACST's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if ACST's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if ACST's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of ACST's dividend in 3 years as they are not forecast to pay a notable one for the Canadian market.
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Jan D'Alvise (66 yo)
Ms. Janelle D’Alvise, also known as Jan, has been an Independent Director of Spectral Medical Inc. since June 03, 2021. She is the Chairman of the board of The ObG Project. She has been the Chief Executive...
CEO Compensation Analysis
Compensation vs Market: Jan's total compensation ($USD428.04K) is above average for companies of similar size in the Canadian market ($USD158.71K).
Compensation vs Earnings: Jan's compensation has been consistent with company performance over the past year.
Experienced Management: ACST's management team is not considered experienced ( 1.3 years average tenure), which suggests a new team.
Experienced Board: ACST's board of directors are considered experienced (4.8 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Dilution of Shares: Shareholders have been substantially diluted in the past year, with total shares outstanding growing by 265.7%.
Acasti Pharma Inc.'s employee growth, exchange listings and data sources
- Name: Acasti Pharma Inc.
- Ticker: ACST
- Exchange: TSXV
- Founded: 2002
- Industry: Pharmaceuticals
- Sector: Pharmaceuticals & Biotech
- Implied Market Cap: CA$67.318m
- Shares outstanding: 44.29m
- Website: https://www.acastipharma.com
Number of Employees
- Acasti Pharma Inc.
- 3009 boulevard de la Concorde East
- Suite 102
- H7E 2B5
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2022/01/26 01:05|
|End of Day Share Price||2022/01/25 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.